-+ 0.00%
-+ 0.00%
-+ 0.00%

Relay Therapeutics Q3 2026 net loss widens 10% year over year to $81.75 million

PUBT·11/04/2026 21:28:00
Listen to the news
Relay Therapeutics Q3 2026 net loss widens 10% year over year to $81.75 million
  • Relay Therapeutics’ third-quarter 2026 net loss widened 10% year over year to $81.75 million.
  • Research and development expenses rose 13% year over year to $77.14 million, primarily due to clinical-trial costs and nonrecurring lease-termination costs.
  • Cash, cash equivalents and investments totaled $848.6 million at September 30, with funding expected to cover operating and capital requirements into 2029.
  • The Phase 3 ReDiscover-2 breast cancer trial is expected to complete enrollment in mid-2027, approximately one year faster than recent benchmarks.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041605PRIMZONEFULLFEED9870412) on November 04, 2026, and is solely responsible for the information contained therein.